Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine

Kiwaki, Takumi; Kataoka, Hiroaki

doi:10.3390/jpm12050695

Cited by 7 publications

(4 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Broadly, 3D culture methods can be classified into scaffold-based consisting of Matrigel or BME embedding, air-liquid interfaces (ALI), and scaffold-free systems. This classification is determined by the presence or absence of a gel substrate and the specific technique used to embed the cells [ 106 , 107 ]. The inclusion of various growth factors dedicated to different tissues and co-cultivation with immune cells are highlighted to replicate the TME, thereby emulating the matrix conditions for 3D culture [ 100 ].…”

Section: In Vitro Drug Screening Methods For Crcmentioning

confidence: 99%

Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

Ahmad Zawawi,

Salleh,

Musa

2024

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a heterogeneous disease. Conventional two-dimensional (2D) culture employing cell lines was developed to study the molecular properties of CRC in vitro. Although these cell lines which are isolated from the tumor niche in which cancer develop, the translation to human model such as studying drug response is often hindered by the inability of cell lines to recapture original tumor features and the lack of heterogeneous clinical tumors represented by this 2D model, differed from in vivo condition. These limitations which may be overcome by utilizing three-dimensional (3D) culture consisting of spheroids and organoids. Over the past decade, great advancements have been made in optimizing culture method to establish spheroids and organoids of solid tumors including of CRC for multiple purposes including drug screening and establishing personalized medicine. These structures have been proven to be versatile and robust models to study CRC progression and deciphering its heterogeneity. This review will describe on advances in 3D culture technology and the application as well as the challenges of CRC-derived spheroids and organoids as a mode to screen for anticancer drugs.

show abstract

Section: In Vitro Drug Screening Methods For Crcmentioning

confidence: 99%

Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

Ahmad Zawawi,

Salleh,

Musa

2024

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

show abstract

“…4,5 Whether dealing with rare tumors or more common primary cancers such as those affecting the head, neck, bladder, lungs, and colorectal areas, organoids and tissue engineering provide valuable tools to understand and address diverse treatment responses and variations among tumors. [6][7][8][9][10] Cytologic techniques offer rapid adequacy interpretation and represent a less invasive and more costefficient solution for the diagnosis and management of lesions. 11,12 They may also be the fundamental basis of obtaining tissues that are atypical, rare, or pose a diagnostic dilemma for further characterization and study via organoids.…”

Section: Organoid Technology Of Rare Tumor Entities and The Significa...mentioning

confidence: 99%

Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques

Abd El‐Salam,

Troulis,

Pan

et al. 2023

Cancer Cytopathology

View full text Add to dashboard Cite

Patient‐derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three‐dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost‐effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine‐needle aspiration to generate tumoroids.

show abstract

“…Colorectal cancer has complex histological features such as glandular structure and mucin production, which are difficult to represent in two-dimensional cellular models. In order to better understand the biology of colorectal cancer and to improve therapeutic outcomes, three-dimensional (3D) culture models, represented by patient-derived organoids (PDOs), have been applied to study colorectal cancer [2]. 5-fluorouracil (5-FU) is a chemotherapeutic agent and one of the most effective and commonly used drugs in CRC treatment, but the non-selectivity of 5-FU can lead to drug resistance as well as limited target concentration.…”

Section: Introductionmentioning

confidence: 99%

Morpho-molecular functional drug response analysis of patient-derived organoids of colorectal cancer

Li,

Krause,

Giardina

et al. 2024

Optical Biopsy XXII: Toward Real-Time Spectroscopic Imaging and Diagnosis

View full text Add to dashboard Cite

Nanoparticle-based drug delivery systems have shown potential for cancer treatment. Due to their size, nanoparticles penetrate into tumors, facilitate drug uptake, enable efficient drug delivery and ensure efficacy at the target site. They present good pharmacokinetics, precisely target tumor cells, reduce side effects and drug resistance. Recently, patient-derived organoids (PDOs) of colorectal cancer (CRC) patients proved to be a valuable tool to study the pathological, physiological, and genetic characteristics of CRC. In particular, they can be employed to test drugs in-vitro in a complex heterogeneous environment. We use UiO-66-NH2 nanoparticles as drug delivery carriers for 5-Fluorouracil (5-FU) to PDOs of CRC to study interactions between organoids and nanoparticles. Since PDOs preserve tumor heterogeneity to a significant extent, we investigate the structural, metabolic, and molecular changes in PDOs across different CRC and the impact of UiO-66-NH2 as carrier for 5-FU with our custom multimodal optical microscope offering complementary co-registered contrast from Optical Coherence Tomography (OCT), Multiphoton Microscopy (MPM), and Raman Microscopy (RM). We examine the interactions between nanoparticles and PDOs of CRC as well as their response to 5-FU. We assess the influence of the drug by extracting morphological features from OCT/MPM images, distinguish PDOs phenotypic differences through RM molecular analysis, identifying alterations in relevant biomarkers such as lipids, proteins, collagen, DNA, further analyze molecular metabolic differences and conduct sample classification. We demonstrate the significant potential of our multimodal imaging system in the analysis of PDOs and nano-medicine effects, enabling high-precision morpho-molecular metabolic analysis and classification.

show abstract

Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine

Cited by 7 publications

References 128 publications

Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques

Morpho-molecular functional drug response analysis of patient-derived organoids of colorectal cancer

Contact Info

Product

Resources

About